
FND Detective Series
The FND Detective Series is a collaborative initiative where volunteers dive into individual research projects focusing on Functional Neurological Disorder (FND) and its surrounding issues. Each volunteer researches a unique topic, producing detailed articles that offer fresh perspectives on FND.
The series has a mission with three distinct aims:
​
-
Advocating for Policy Change: The research will assist in informing petitions that push for better healthcare policies and increased support for FND patients.
-
Building Future Research: By identifying gaps and generating new insights, the series paves the way for innovative research projects to improve FND treatment and understanding.
-
Enhancing Education: The series provides educational content aimed at raising awareness, educating healthcare professionals, and supporting individuals affected by FND.
​​
Through its focused research and advocacy, the FND Detective Series seeks to shape a future where FND is better understood, managed, and supported.
​
Want more details? See the blog post.
Disclaimer: The articles in our FND Detective Series are created by volunteer contributors. These articles have not undergone formal peer review and do not represent official medical advice, diagnosis, or treatment recommendations. The information provided reflects the contributors’ independent research, perspectives, and interpretations and is not intended as a substitute for professional medical guidance.
​
The content on this website is intended to explore ideas, raise questions, spark conversation, and highlight resources related to Functional Neurological Disorder (FND). All views expressed are those of the individual authors and do not necessarily represent the official views, policies, or positions of Not Defined By FND.
​
While we aim to provide accurate and supportive information, the content should not be considered definitive scientific conclusions. For medical questions or personal care decisions, always consult a qualified healthcare professional. If you are experiencing a medical emergency, please contact your local emergency services immediately.
You can find the articles on our blog, Medium, and Academia. Just choose the platform you prefer and click the corresponding link to read.
Functional Neurological Disorder as a Disorder of Network Integration and
Predictive Inference
Author: Olivia Taylor Date: 10/13/2025
Functional Neurological Disorder (FND) presents with genuine, often disabling
neurological symptoms—e.g., limb weakness, tremor, seizures—without a structural lesion that
accounts for them. Modern practice emphasizes positive clinical signs (e.g., Hoover’s sign,
tremor entrainment) rather than a “rule-out-everything” diagnosis (Hallett et al., 2022; Voon et
al., 2016). Historically cast as “psychological,” contemporary models frame FND as disrupted
integration across large-scale brain networks involved in bodily awareness, movement planning,
agency, attention/salience, and executive control (Stone et al., 2021; Perez et al., 2021). This
paper argues that FND symptoms emerge from aberrant network interactions, not a single
damaged node (Stone et al., 2021).
A useful unifying perspective is predictive processing: symptoms reflect maladaptive
priors/expectations and attentional weighting applied to interoceptive and sensorimotor signals.
In FND, abnormal precision (confidence) may be assigned to misleading internal cues,
destabilizing perception of the body and control of action. Here, “precision” (or “confidence”)
refers to how strongly the brain weights a signal or prediction when deciding what is happening;
too much precision on noisy internal cues can overpower corrective sensory evidence and bias
experience toward non-movement or non-agency (Stone et al., 2021; Perez et al., 2021).
The Salience (Cingulo-Insular) Network (SN/CIN)
The salience network acts like the brain’s “relevance filter,” deciding what deserves
attention right now and shifting resources accordingly. Its hubs, the anterior insula and anterior
cingulate cortex (ACC), link body signals (like heartbeat, muscle tension, visceral sensations)
with emotion and goal-directed control (Craig, 2009; Stone et al., 2021). In FND, this filter
appears overreactive for internal threat cues: interoceptive sensations are marked as highly
important, attention is drawn inward, and competing goals (like fluid movement) get crowded
out. Empirically, this shows up as atypical coupling between salience hubs and
sensorimotor/control networks and aligns with common clinical features such as anxiety and
difficulties identifying/labeling internal states (alexithymia) (Hallett et al., 2022; Perez et al.,
2021; Aybek et al., 2015). The issue is not a linear cause-and-effect sequence but a broader
miscalibration in how the system assigns importance to internal versus external cues,
especially under uncertainty (Stone et al., 2021).
Supplementary Motor Area (SMA) and Movement Initiation
The supplementary motor complex—encompassing pre-SMA and SMA
proper—coordinates the preparation, sequencing, and initiation of voluntary movement,
particularly when actions are internally generated rather than purely stimulus-driven. In a
predictive-processing frame, these regions help specify forward models of the intended action
and issue efference copies that predict the sensory/proprioceptive consequences of the movement
(Stone et al., 2021). Successful execution depends on a tight communication loop among
pre-SMA/SMA, primary motor cortex, basal ganglia, cerebellum, and parietal comparators, with
top-down precision signals determining which motor intentions come to fruition (Voon et al.,
2016; Perez et al., 2021).
In FND, available evidence is most consistent with an instability at the interface between
intention and enactment of movement. Preparatory activity can be present but expressed weakly
in behavior, suggesting a decoupling between motor readiness and the subjective experience of
willing the movement (Edwards et al., 2011; Maurer et al., 2016). Altered coupling between
SMA/pre-SMA and parietal–temporal nodes (including agency-related regions) fits a picture in
which prediction and feedback are not being integrated with the usual confidence. When the
salience network biases attention toward internal threat signals, this mis-calibration is amplified:
the system prioritizes monitoring and “checking” over fluid execution, and the intended
movement is either inhibited or experienced as not truly self-generated (Hallett et al., 2022;
Perez et al., 2021).
This account supports why physiotherapy that minimizes self-focused monitoring and restores
automaticity can be effective. External cueing (rhythm, targets), dual-tasking, graded
complexity, and an external focus of attention reduce the maladaptive precision assigned to
interoceptive “error” signals and allow the SMA–parietal–cerebellar communication loop to
re-stabilize. When movement is shaped under conditions that discourage excessive internal error
monitoring, individuals more readily re-experience actions as intended and voluntary (Stone et
al., 2021; Hallett et al., 2022).
Temporoparietal Junction (TPJ) and Sense of Agency (SoA)
The temporoparietal junction (TPJ) contributes to the sense of agency (SoA) by integrating
multisensory predictions (derived from efference copies) with the reafferent feedback, which is
the sensory information that returns to the brain following actions. Positioned at the confluence
of visual, vestibular, and somatosensory streams, the TPJ helps maintain a coherent body schema
and evaluates whether outcomes match intentions (Perez et al., 2021). Agency, in this view,
emerges when predicted and observed consequences are sufficiently aligned and weighted with
appropriate precision (Baek et al., 2022; Stone et al., 2021).
Findings in FND indicate abnormal TPJ participation in these comparisons, with connectivity to
sensorimotor and frontal control regions altered across cohorts and phenotypes. Rather than a
single direction of effect, the pattern suggests a mismatch in how predictive and feedback
signals are integrated and trusted. When salience circuitry up-weights bodily noise and control
networks fail to recalibrate, TPJ computations are performed on noisy inputs with skewed
precision, increasing the likelihood that self-generated actions feel alien. The clinical
phenomenology of “I can’t make it move,” or “it moves but not by my will,” naturally follows
from this imbalance: the comparator does not recognize the action as self-produced, even when
the motor system can execute it (Weber et al., 2025; Baek et al., 2022; Hallett et al., 2022).
Therapeutic strategies that restore reliable prediction–feedback contingencies therefore
make mechanistic sense. Techniques that provide accurate, synchronous visuo-proprioceptive
feedback (e.g., action observation, video feedback, mirror-based tasks when appropriate) and that
grade exposure to self-initiated movement under an external focus help re-calibrate TPJ
computations. As the system repeatedly experiences consistencies between intended and
observed outcomes without threat-biased monitoring, agency strengthens and symptoms subside
(Stone et al., 2021; Hallett et al., 2022).
Dorsolateral Prefrontal Cortex (DLPFC) / Frontoparietal Control
The dorsolateral prefrontal cortex (DLPFC) is an important node within the
frontoparietal control network that provides top-down control, helping the system decide how
much weight to give interoceptive and sensorimotor signals at any moment. In a
predictive-processing frame, this involves calibrating the precision of competing hypotheses
about bodily states and actions. When this control is compromised, misleading internal cues
(amplified by salience circuitry) retain excessive influence, and corrective evidence is
underweighted. Clinically, that looks like persistent convictions of “something is wrong with my
body” and a persistent sense of non-agency, even when motor pathways are capable of producing
movement (Stone et al., 2021; Perez et al., 2021).
Converging work places the DLPFC as the link between attention allocation, conflict
monitoring, and metacognitive updating, processes that should suppress maladaptive prior
expectations and support re-estimation when predictions fail. In FND, alterations within this
network can weaken the system’s ability to down-regulate threat-biased interoception and to
reconcile prediction errors arising from disrupted interactions among the salience network,
supplementary motor regions, and temporoparietal nodes. The result is not simply a failure to
move but a failure to re-experience movement as intended and self-generated. This model
complements evidence of abnormal SMA–parietal/TPJ coupling by specifying how
DLPFC-mediated control would ordinarily stabilize intention–action coherence and re-establish
confidence in voluntary control (Baek et al., 2022; Perez et al., 2021).
Therapeutically, this positioning of DLPFC within the control network explains why
explanatory models, attention-shifting physiotherapy, and CBT-informed strategies can be
effective: they all work, in part, by retuning precision and re-weighting misleading bodily
predictions under active, goal-directed control. It also motivates cautious exploration of
adjunctive neuromodulation aimed at control or agency nodes as potential stabilizers of the
network dynamics that support accurate bodily inference, as a complement to behavior-based
retraining (Perez et al., 2015; Stone et al., 2021).
Discussion: A Systems-Level Account
FND appears to be an emergent property of disrupted integration among salience,
sensorimotor/agency, and control networks. Explored through predictive processing, symptoms
arise when maladaptive priors and attentional weighting are applied to interoceptive and
sensorimotor evidence, producing compelling but misleading inferences about the body—for
example, that a limb cannot move or that a tremor is entirely involuntary. Clinically,
abnormalities within the salience network bias attention toward internal signals and threat,
differences in coupling between SMA/pre-SMA and parietal/TPJ nodes destabilize the coherence
between intention and action and erode the SoA, and alterations in frontoparietal control limit the
system’s capacity to re-weight misleading priors or to update beliefs in the face of contradictory
evidence (Stone et al., 2021; Hallett et al., 2022). This account does not require the nervous
system to be “normal” in every respect, but it emphasizes that the characteristic symptoms reflect
network-level dysfunction rather than a focal lesion (Perez et al., 2021; Voon et al., 2016).
Future Directions and Conclusion
Progress depends on moving beyond static group comparisons toward methods that
reveal how signals flow through the system. Dynamic connectivity analyses, coupled with
computational models of predictive coding and precision weighting, can show when and where
salience, sensorimotor, and control networks miscommunicate during symptom expression and
recovery. Studies should also stratify participants by phenotype, such as functional weakness,
tremor, or seizures, because connectivity patterns and treatment responses likely differ across
these groups (Hallett et al., 2022). Practically, that means planning studies in advance with clear
hypotheses, ensuring adequate sample sizes, and measuring both how the brain–behavior
mechanisms change and whether patients actually improve (Perez et al., 2021).
Within this framework, neuromodulation can be tested as an adjunct to physiotherapy and
CBT-informed rehabilitation rather than as an independent intervention, with protocols targeted
to specific nodes (for example, rTPJ, motor, or control centers) and evaluated for their ability to
stabilize network interactions that support accurate bodily inference and voluntary control (Perez
et al., 2015; Stone et al., 2021).
References
Aybek, S., Nicholson, T. R., O’Daly, O., Zelaya, F., Kanaan, R. A., et al. (2015).
Emotion–motion interactions in conversion disorder: An fMRI study. PLOS ONE, 10(4),
e0123273. doi: 10.1371/journal.pone.0123273
Baek, K., Donamayor, N., Morris, L. S., Strelchuk, D., Mitchell, S., Mikheenko, Y., ... & Voon,
V. (2022). The self-agency network: Neural correlates of sense of agency in healthy
controls and patients with functional neurological disorder. Brain and Behavior, 12(9),
e2733. doi: 10.1002/brb3.2733
Craig, A. D. (2009). How do you feel—now? The anterior insula and human awareness. Nature
Reviews Neuroscience, 10(1), 59–70. doi: 10.1038/nrn2555
Edwards, M. J., Moretto, G., Schwingenschuh, P., Katschnig, P., Bhatia, K. P., & Haggard, P.
(2011). Abnormal sense of intention preceding voluntary movement in patients with
psychogenic tremor. Neuropsychologia, 49(9), 2791–2793. doi:
10.1016/j.neuropsychologia.2011.05.021
Hallett, M., Aybek, S., Dworetzky, B. A., McWhirter, L., Staab, J. P., & Stone, J. (2022).
Functional neurological disorder: New subtypes and shared mechanisms. The Lancet
Neurology, 21(6), 537–550. doi: 10.1016/S1474-4422(21)00422-1
Maurer, C. W., LaFaver, K., Ameli, R., Epstein, S. A., Hallett, M., & Horovitz, S. G. (2016).
Impaired supplementary motor area inhibition in functional movement disorders: A
preliminary study. PLOS ONE, 11(7), e0158556. doi: 10.1371/journal.pone.0158556
Perez, D. L., Dworetzky, B. A., Dickerson, B. C., Leung, L., Cohn, R., Baslet, G., & Silbersweig,
D. A. (2015). An integrative neurocircuit perspective on psychogenic nonepileptic seizures and
functional movement disorders: Neural functional unawareness. Clinical EEG and Neuroscience,
46(1), 4–15. doi: 10.1177/1550059414555905
Perez, D. L., Nicholson, T. R., Asadi-Pooya, A. A., Begue, I., Butler, M., Carson, A. J., David,
A. S., Deeley, Q., Diez, I., Edwards, M. J., Espay, A. J., Gelauff, J. M., Hallett, M., Horovitz, S.
G., Jungilligens, J., Kanaan, R. A., Tijssen, M. A., & Aybek, S. (2021). Neuroimaging in
functional neurological disorder: State of the field and research agenda. The Lancet Psychiatry,
8(10), 826–841. doi: 10.1016/S2215-0366(21)00303-3
Stone, J., Carson, A., & Hallett, M. (2021). A framework for understanding the pathophysiology
of functional neurological disorder. The Lancet Psychiatry, 8(9), 819–829. doi:
10.1016/S2215-0366(21)00343-4
Voon, V., Cavanna, A. E., Coburn, K., Sampson, S., Reeve, A., & LaFrance, W. C., Jr. (2016).
Functional neuroanatomy and neurophysiology of functional neurological disorders
(conversion disorder). Journal of Neuropsychiatry and Clinical Neurosciences, 28(3),
168–190. doi: 10.1176/appi.neuropsych.14090217
Weber, S., Cartoni, E., Gaggioni, L., Turri, F., Wiest, R., & Aybek, S. (2025). Altered brain
network dynamics in functional neurological disorder: The role of the temporoparietal
junction. Brain, 148(1), 1–15. doi: 10.1093/brain/awae999
How Technology Helps in Diagnosing Functional Neurological Disorder
Author: Zai Gao Date: 01/08/2025
Technology has revolutionized how doctors diagnose and treat medical conditions. For many neurological disorders, tools like MRI scans and EEG tests provide detailed insights into the brain and nervous system, helping pinpoint structural or electrical issues that cause symptoms. For example, MRIs can reveal strokes, tumors, or multiple sclerosis, while EEGs can detect abnormal brain activity linked to epilepsy. These tools often give doctors clear, objective answers. But Functional Neurological Disorder (FND) is a little different.
FND doesn’t have a clear structural cause—there’s no visible damage to the brain or spinal cord, no tumor, no stroke (click here to learn more about symptoms of FND). It’s not something you can spot on an MRI like you would for some other conditions. However, recent studies have shown that there are some differences between the brains of FND patients and others, particularly in neurometabolites. These findings are promising, but further research is needed to explore the details. So, in general, just as there’s no single biomarker for FND, there’s also no single test that can definitively confirm, “This is FND.”
High-tech tools play an important role in diagnosing FND. They help rule out other conditions that might mimic FND and, in some cases, give subtle clues about what’s happening in the brain. This combination of advanced technology and skilled clinical observation is what makes diagnosing FND such a unique process. So, how do these tools work, and what can they really tell us about FND? Let’s explore!
​
The Role of MRI in Diagnosing FND
​
MRI, or Magnetic Resonance Imaging, is one of the most advanced tools doctors have for looking inside the brain and spinal cord (learn what happens during an MRI and how to prepare for an MRI here). It uses powerful magnets and radio waves to create detailed pictures, showing everything from soft tissues to blood vessels. For many neurological conditions, like strokes, brain tumors, or multiple sclerosis, an MRI can reveal structural damage or abnormalities that explain a patient’s symptoms (see which parts of body could go through a MRI scan here). But here’s the twist: when it comes to FND, MRI scans almost always come back normal.
At first, this might feel frustrating or confusing—how can your symptoms be real if the test shows nothing wrong? But a normal MRI result is actually a critical step in diagnosing FND. Why? Because it helps rule out other serious conditions that could be causing similar symptoms. For instance, if someone experiences sudden muscle weakness, numbness, or tremors, an MRI can confirm that there’s no physical injury, tumor, or disease affecting the brain or spinal cord. This reassurance allows doctors to shift their focus to functional issues. It’s like crossing off other possibilities on the list, narrowing the path toward a better understanding of your condition.
​
EEG: Testing Brain Activity
​
Another tool doctors commonly use is an EEG, or Electroencephalogram (here is an EEG demonstration video if you’re curious). This test measures the brain’s electrical activity by placing small sensors on your scalp to detect and record patterns. It’s often used for patients who experience seizures, as it helps determine whether the seizures are caused by epilepsy or another condition.
​
For epilepsy, an EEG typically shows abnormal electrical activity, such as spikes or waves, that indicate disruptions in how the brain is functioning. But with FND, the EEG usually shows normal brain activity—even during an episode. This difference is a key clue for doctors. It helps them rule out epilepsy and focus on diagnosing FND.
Doctors may even use EEGs alongside other tests, like video monitoring, to observe your symptoms in real-time. For example, if a functional seizure occurs during the EEG, the recording can show how your brain’s activity stays normal despite the outward symptoms. This combination of tools helps doctors better understand what’s happening and strengthens their confidence in the diagnosis.
​
Functional MRI (fMRI) and Emerging Tools
​
Functional MRI, or fMRI, takes traditional MRI to a whole new level by measuring brain activity in real time. Unlike a standard MRI, which captures detailed images of the brain’s structure, an fMRI tracks changes in blood flow, revealing which areas of the brain are more active during specific tasks. This allows doctors and researchers to "see" the brain in action. Although fMRI isn’t yet used as a routine diagnostic tool for FND, it’s opening up exciting possibilities for the future. Researchers are continuing to study these brain activity patterns, hoping to develop more precise ways to diagnose FND and tailor treatments based on how the brain functions in individual patients.
​
fMRI isn’t the only emerging tool. Technologies like magnetoencephalography (MEG) are also being explored. MEG measures the magnetic fields produced by the brain’s electrical activity and can provide incredibly detailed maps of how the brain is working in real time. Other advanced neuroimaging techniques, like diffusion tensor imaging (DTI), which maps how different parts of the brain are connected, are also being studied. While these technologies aren’t widely available for diagnosing FND yet, they represent a glimpse of the future. Imagine a day when we can use these tools to not only understand the unique way your brain functions but also to develop personalized treatments that target the specific pathways involved in your symptoms. For now, emerging tools remain at the cutting edge of research, but their potential to transform how we understand and manage FND is truly inspiring.
​
(For more information, here is a comprehensive study published in 2021 summarizes the output of the first International FND Neuroimaging Workgroup meeting on June 17th, 2020. It outlines many novel biologically and psychologically-informed treatments.)
​
References
​
“Epilepsy.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 14 Oct. 2023, www.mayoclinic.org/diseases-conditions/epilepsy/symptoms-causes/syc-20350093.
​
“Functional Neurological Disorder (FND) | NHS Inform.” NHS INFORM, www.nhsinform.scot/illnesses-and-conditions/brain-nerves-and-spinal-cord/functional-neurological-disorder/. Accessed 9 Jan. 2025.
“Magnetic Resonance Imaging (MRI).” Johns Hopkins Medicine, 22 May 2024, www.hopkinsmedicine.org/health/treatment-tests-and-therapies/magnetic-resonance-imaging-mri.
“MRI.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 9 Sept. 2023, www.mayoclinic.org/tests-procedures/mri/about/pac-20384768.
Perez et al. “Neuroimaging in Functional Neurological Disorder: State of the Field and Research Agenda.” NeuroImage. Clinical, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/34215138/. Accessed 8 Jan. 2025.
UWGB Psychology. “Electroencephalogram (EEG) Demonstration.” YouTube, YouTube, www.youtube.com/watch?v=-5djHvFo7IQ. Accessed 8 Jan. 2025.
Why Diagnosing Functional Neurological Disorders is hard?
Author: Zai Gao Date: 12/16/2024
Diagnosing Functional Neurological Disorder (FND) can be really tough, and that’s because there isn’t a single test or biomarker that can give us a clear “yes” or “no” answer. Let’s break that down.
Imagine genetic testing. For some conditions, like sickle cell anemia, a simple test can confirm the diagnosis. According to the National Institutes of Health, sickle cell anemia is a blood disorder where red blood cells become rigid and shaped like sickles, causing pain and potential damage to organs (Check out more about sickle cell here). This disorder happens because of a mutation in one specific gene, so doctors can run a targeted genetic test to see if that mutation is there.
Now, what about biomarkers? Biomarkers are measurable signs in the body that give us clues about our health. Think of things like blood pressure, body temperature, pulse, or heart rate—these are examples of physiological biomarkers. There are also molecular biomarkers, like red blood cell counts or hormone levels. Take type 2 diabetes, for instance. It’s often diagnosed by measuring blood sugar levels, which is a clear, measurable indicator (Learn about how to diagnose type 2 diabetes here).
But with FND, it’s different. There isn’t a specific test result or biomarker that tells doctors if someone does or doesn’t have FND. Without a clear physical indicator, doctors have to consider lots of different factors. This is where things can get complicated, and sometimes mistakes happen.
What Are the DSM-5 and ICD-11, and Why Do They Matter in Diagnosing FND?
You may have heard of the DSM-5 or the ICD-11 when talking about medical or mental health diagnoses, but what exactly are these manuals, and why are they so important in diagnosing conditions like FND?
Let’s start with the DSM-5. The DSM-5 stands for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. It’s basically the “bible” for mental health professionals in the United States and is published by the American Psychiatric Association. It covers everything from anxiety disorders to depression to FND. Think of it as a checklist that doctors use to figure out what condition a patient might have.
(If you want to dive into some medical jargon, you can check out the DSM online here. Note: this website is for educational purposes only, always consult a qualified doctor if you need medical advice or support.)
The ICD-11, on the other hand, stands for the International Classification of Diseases, 11th Revision, and it was created by the World Health Organization (WHO). Unlike the DSM-5, the ICD-11 is used all over the world and covers not only mental health disorders but also all kinds of medical conditions. It helps make sure that diseases and disorders are diagnosed in a standard way, no matter where you are. See ICD-11 for FND here.
When doctors need to diagnose something tricky like FND, they turn to the DSM-5 or ICD-11. These manuals provide clear guidelines on what symptoms need to be present for a diagnosis. For example, if a patient shows signs like sudden muscle weakness or tremors, the doctor will check the DSM-5 or ICD-11 to see if the patient’s symptoms match the criteria for FND.
(If you’re interested in learning more about the criteria for FND from both manuals, take a look at this study here. For a quick and clear overview, head straight to Table 1.)
However, the DSM-5 and ICD-11 also have some downsides. The criteria in these manuals can be quite strict, and not everyone’s symptoms fit neatly into these categories, they also don’t always account for how cultural or background differences can influence how symptoms show up. For example, certain people express emotional distress through physical symptoms, like stomach pain or headaches, rather than describing feelings of anxiety or sadness. Additionally, labels can also oversimplify complex disorders. For instance, even though FND is a real disorder with physical symptoms, some people might wrongly think it’s “all in someone’s head.”
Common Tests for Diagnosing Functional Neurological Disorders
​
Diagnosing FND involves specific tests that look for signs of a functional issue rather than a structural problem, like damage to nerves or muscles. Let’s explore some common tests doctors use and what they mean.
One of the most common tests is called Hoover’s Sign. This test is used to assess leg weakness. If someone says they can’t lift one of their legs, the doctor might ask them to press down with their other leg, as if stepping on a gas pedal. Normally, pressing down with one leg causes the other leg to lift automatically because of how our muscles work together. However, in someone with FND, the leg might not lift when asked to move intentionally, but it might still lift when the person is distracted by pressing down with the other leg. This inconsistency is a key feature of FND.
Another helpful test is for give-way weakness. In this test, the doctor applies steady resistance to the patient’s arm or leg and asks them to push or hold their strength. In someone with FND, the muscle might feel strong at first but then suddenly “give way” or weaken without warning. This weakness often comes and goes quickly. In contrast, weakness caused by a neurological condition like a stroke would stay consistent throughout the test.
There are many other possible tests depending on the patient’s symptoms, such as the Romberg test, Gait testing, etc. These tests are important because they help doctors identify positive signs of FND rather than just ruling out other conditions. This approach allows for a confident diagnosis and avoids unnecessary tests or treatments.
It’s worth noting that FND is a real and treatable condition, even though it doesn’t have a structural cause like a damaged nerve or muscle. If you’re going through these tests, it’s natural to feel unsure or even nervous, but understanding what the doctor is looking for can make the process clearer. The goal is to understand your symptoms better and start the journey toward effective treatment.
References
-
2025 ICD-10-CM Diagnosis Code F44.6: Conversion Disorder with Sensory Symptom or Deficit, www.icd10data.com/ICD10CM/Codes/F01-F99/F40-F48/F44-/F44.6. Accessed 14 Dec. 2024.
-
“Educational Resources.” Psychiatry.Org - Educational Resources, www.psychiatry.org/psychiatrists/practice/dsm/educational-resources. Accessed 14 Dec. 2024.
-
First, Michael B, et al. “An Organization- and Category-Level Comparison of Diagnostic Requirements for Mental Disorders in ICD-11 and DSM-5.” World Psychiatry : Official Journal of the World Psychiatric Association (WPA), U.S. National Library of Medicine, Feb. 2021, pmc.ncbi.nlm.nih.gov/articles/PMC7801846/
-
“Gait & Balance Problems.” FND Hope International, 9 Sept. 2020, fndhope.org/fnd-guide/symptoms/gait-balance-problems/.
-
“Hoovers Sign (Neurological).” Physiopedia, www.physio-pedia.com/Hoovers_Sign_(Neurological). Accessed 14 Dec. 2024.
-
professional, Cleveland Clinic medical. “Romberg Test for Balance Issues: What It Is & Types.” Cleveland Clinic, 19 Nov. 2024, my.clevelandclinic.org/health/diagnostics/22901-romberg-test.
-
“Type 2 Diabetes.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 14 Mar. 2023, www.mayoclinic.org/diseases-conditions/type-2-diabetes/diagnosis-treatment/drc-20351199#.
-
“What Is Sickle Cell Disease?” National Heart Lung and Blood Institute, U.S. Department of Health and Human Services, www.nhlbi.nih.gov/health/sickle-cell-disease. Accessed 14 Dec. 2024.



